CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 164 filers reported holding CLOVIS ONCOLOGY INC in Q4 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,225,000 | +57.1% | 680,855 | +289.1% | 0.02% | +88.9% |
| Q3 2021 | $780,000 | -84.8% | 175,000 | -80.3% | 0.01% | -86.6% |
| Q2 2021 | $5,147,000 | +4897.1% | 887,500 | +4008.8% | 0.07% | +3250.0% |
| Q4 2020 | $103,000 | -72.8% | 21,600 | -66.9% | 0.00% | -77.8% |
| Q3 2020 | $379,000 | -88.9% | 65,300 | -87.1% | 0.01% | -92.1% |
| Q2 2020 | $3,426,000 | -53.7% | 507,500 | -56.4% | 0.11% | -72.8% |
| Q1 2020 | $7,406,000 | -41.6% | 1,164,300 | -4.3% | 0.42% | -1.4% |
| Q4 2019 | $12,680,000 | +379.8% | 1,216,300 | +80.7% | 0.42% | +210.2% |
| Q3 2019 | $2,643,000 | -1.2% | 673,000 | +273.9% | 0.14% | +1.5% |
| Q2 2019 | $2,676,000 | -74.0% | 180,000 | -56.5% | 0.14% | -76.1% |
| Q1 2019 | $10,276,000 | +436.6% | 414,100 | +535.1% | 0.57% | +434.0% |
| Q3 2018 | $1,915,000 | – | 65,200 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |